<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">SMF</journal-id>
      <journal-title-group>
        <journal-title>Schweizerisches Medizin-Forum</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1424-4020</issn>
      <issn pub-type="ppub">1424-3784</issn>
      <publisher>
        <publisher-name>EMH Schweizerischer Ärzteverlag AG</publisher-name>
        <publisher-loc>Farnsburgerstrasse 8
CH-4132 Muttenz</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">08809</article-id>
      <article-id pub-id-type="doi">10.4414/smf.2022.08809</article-id>
      <article-categories>
        <!-- rubric -->
        <subj-group subj-group-type="Article Type">
          <subject>Der besondere Fall</subject>
        </subj-group>
        <!-- topics -->
        <subj-group subj-group-type="Classification">
          <subject>Intensivmedizin</subject>
          <subject>Klinische Pharmakologie und Toxikologie</subject>
          <subject>Labormedizin</subject>
          <subject>Notfallmedizin</subject>
          <subject>Pneumologie</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Akute Cyanidintoxikation durch Amygdalin</article-title>
      </title-group>
      <contrib-group>
        <contrib id="author-1" contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Resech</surname>
            <given-names>Friderike</given-names>
          </name>
          <email>friderike.resech@gmail.com</email>
          <aff>UNZ | Fischerweg 18 | Bern | 3012 | SWITZERLAND | +410786345797</aff>
        </contrib>
        <contrib id="author-2" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Lehmann</surname>
            <given-names>Beat</given-names>
          </name>
          <email/>
          <aff>Inselspital Universitätsspital Bern Universitäres Notfallzentrum</aff>
        </contrib>
        <contrib id="author-3" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Weinmann</surname>
            <given-names>Wolfgang</given-names>
          </name>
          <email/>
          <aff>Institut für Rechtsmedizin, Forensische Toxikologie und Chemie, Universität Bern</aff>
        </contrib>
        <contrib id="author-4" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Klingberg</surname>
            <given-names>Karsten</given-names>
          </name>
          <email/>
          <aff>Inselspital Universitätsspital Bern Universitäres Notfallzentrum</aff>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" date-type="pub" iso-8601-date="2022.01.19">
        <day>19</day>
        <month>01</month>
        <year>2022</year>
      </pub-date>
      <volume>22</volume>
      <issue>0304</issue>
      <fpage>75</fpage>
      <lpage>77</lpage>
      <permissions>
        <copyright-statement>Copyright: EMH Schweizerischer Ärzteverlag AG</copyright-statement>
        <copyright-year>2022</copyright-year>
        <copyright-holder>EMH Schweizerischer Ärzteverlag AG</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p>"Swiss Medical Forum" is an open access publication of EMH published in accordance with the terms of the Creative Commons licence attribution - NonCommercial - NoDerivatives 4.0 International. You are free to share, copy and redistribute the material in any medium or format under the following terms:</license-p>
          <license-p>Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.</license-p>
          <license-p>NonCommercial — You may not use the material for commercial purposes.</license-p>
          <license-p>NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.</license-p>
          <license-p>"Non-commercial" means not primarily intended for or directed towards commercial advantage or monetary compensation. The incorporation of publications in commercial products, the use of publications to advertise for commercial products or services and any other usage that directly or indirectly pursues commercial interests is subject to the express previous consent of the publishing house as part of a written agreement.</license-p>
          <license-p>Please send us your request in writing. Exact indication of the publication from which you would like to reproduce material and detailed information about its intended use help to facilitate and expedite request processing.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="article" xml:lang="de">
        <p>Fallvorstellung einer Cyanidintoxikation durch Amygdalin aus Nahrungsergänzungsmittel als komplementäre Therapie in der Onkologie.
Eine Cyanidintoxikation sollte als Differentialdiagnose bei einer Laktatazidose mit einbezogen werden.
Der beschriebene Fall verdeutlicht die Wichtigkeit der erweiterten Medikamentenanamnese und Kenntnis über unerwünschte Nebenwirkungen, auch Nahrungsergänzungsmittel oder komplementärmedizinische Präparate können ein nicht unerhebliches Vergiftungs- und Nebenwirkunspotential besitzen
Die Behandlung einer Cyanidintoxikation besteht primär aus Sauerstoffgabe, symptomatischer und supportiver Therapie, bei schweren Verläufen Verabreichung der Antidots Hydroxocobalamin und/oder Natriumthiosulfat, eine Rücksprache mit der Tox Info Suisse ist in jedem Fall empfehlenswert</p>
      </abstract>
    </article-meta>
  </front>
  <body/>
  <back/>
</article>
